查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827373

分子診斷市場（按產品、技術、檢體類型、測試類型、應用和最終用戶分類）—2025-2032 年全球預測

Molecular Diagnostics Market by Offering, Technology, Specimen Type, Test Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年分子診斷市場規模將成長至 816 億美元，複合年成長率為 14.29%。

主要市場統計數據
基準年2024年 280.2億美元
預計2025年 318.6億美元
預測年份：2032年 816億美元
複合年成長率（%） 14.29%

探索分子診斷市場基礎：創新、臨床促進因素和醫療保健服務的新機會

分子診斷技術憑藉其在基因和分子層面上檢測、表徵和監測疾病的卓越精確度，已成為現代醫療保健服務的基石。該領域涵蓋了廣泛的檢測方法和分析平台，旨在識別特定的基因突變、病原體和生物標記物，從而實現個人化治療策略並改善患者預後。檢測靈敏度的提高，加上定序和先進影像技術成本的下降，正促使分子診斷工具在臨床實驗室、研究機構和照護現場中廣泛應用。

次世代定序、增強型聚合酵素鏈鎖反應和質譜技術的突破推動了檢測能力的擴展，同時法律規範也進行了調整，以加快創新診斷方法的核准。實驗室基礎設施和數位化整合的同步投資正在增強數據系統的互通性，促進患者資訊的無縫流動和快速的臨床決策。此外，診斷學和治療學的融合（通常稱為治療診斷學）正將分子檢測置於標靶治療通訊協定的核心地位。

展望未來，不斷變化的監管格局、報銷策略和臨床需求之間的相互作用將決定市場的成長軌跡。相關人員必須克服複雜的營運挑戰，包括擴充性、品管和供應鏈彈性，同時利用癌症、感染疾病和基因篩檢等新興應用帶來的機會。分子診斷的整體發展動能也顯示了其在重塑患者照護模式和推動精準醫療新前沿方面發揮的關鍵作用。

從個人化醫療的整合到臨床測試的監管演變和技術融合，揭示重新定義分子診斷的顛覆性轉變

在檢測技術、數據分析和治療整合的推動下，分子診斷領域正在經歷翻天覆地的變化。隨著基因組分析和生物標記引導治療在腫瘤學和罕見疾病管理中變得至關重要，個人化醫療正從理論願景走向現實。數位病理學和人工智慧平台簡化了影像解讀和預測建模，提高了診斷準確性，進一步促進了這項變革。

為了應對這一轉變，監管機構正在製定適應性路徑，旨在加快高影響力檢測的市場准入，但同時，對臨床驗證和上市後監管的審查也日益嚴格。同時，成本控制壓力和對真實世界證據的需求迫使製造商透過基於結果的研究來證明其價值。 COVID-19疫情證明了分子診斷開發商在擴大高通量檢測生產方面的靈活性，並成為公私合作應對緊迫衛生危機的催化劑。

因此，相關人員正在見證去中心化趨勢與中心化檢測能力的融合。 POC平台日趨成熟，提供快速的周轉時間和易用性，而中心化實驗室則不斷突破多重偵測和超高通量定序的界限。這種二元性將催生一個更強大的診斷生態系統，既能滿足常規篩檢需求，又能滿足大規模監測需求。因此，市場相關人員正在重新評估其產品組合，並建立策略聯盟，以應對這些顛覆性趨勢，並確保其在快速變化的環境中保持韌性和相關性。

美國新關稅政策對分子診斷供應鏈的綜合影響及2025年戰略製造業重組評估

預計到2025年，美國關稅政策的變化將對分子診斷產業的成本結構和供應鏈策略產生重大影響。隨著進口試劑、設備和輔助零件關稅的提案，製造商和實驗室正在為可能轉嫁給醫療服務提供者和患者的投入成本增加做準備。這種情況凸顯了策略性採購和供應基礎多元化的必要性，以減輕關稅帶來的價格壓力。

為此，一些儀器製造商正在探索本地化組裝業務或建立國內試劑生產設施等方案。雖然這些措施可以減輕關稅負擔，但可能需要大量的資本投入和較長的時間才能達到法規合規要求。同時，診斷開發商正在積極與經銷商談判，以達成長期供應協議，採用雙重採購安排，並探索關鍵材料的近岸外包機會。

這些措施的累積效應可能會重塑競爭動態，擁有強大垂直整合能力和供應鏈敏捷性的公司將獲得成本優勢。同時，規模較小的公司可能難以消化上調的關稅，同時又不損害盈利或將成本轉嫁給最終用戶。政策的不確定性進一步加劇了投資決策的複雜性，迫使相關人員模擬各種關稅情境並建立緊急框架。在這種情況下，從原料供應商到最終用戶實驗室的整個價值鏈的協作對於維持尖端分子診斷解決方案的可近性和確保患者照護的連續性至關重要。

深入研究所提供的技術、檢體類型、測試格式、應用領域和最終用戶概況，以推動分子診斷的策略性細分

仔細觀察市場就會發現，每個細分市場都提供獨特的價值主張：儀器提供硬體支撐，套件和試劑盒提供生化特異性，軟體和服務支援數據管理和提案分析。技術範圍廣泛，包括用於染色體和基因圖譜的螢光雜合反應、用於蛋白質組分析的質譜技術、用於平行標靶篩檢的微陣列分析技術、EXOME、RNA、標靶和全基因組的次世代定序，以及涵蓋數位、多重和即時變異的聚合酵素鏈鎖反應平台。

檢體類型的多樣性反映了分子檢測的多樣性，從血液和腦脊髓液到鼻咽拭子、唾液、糞便、組織切片檢查和尿液，每種檢測方法都有不同的預處理和分析要求。檢測類型的分類凸顯了實驗室模式與中央、醫院和獨立實驗室基礎設施以及針對快速、分散診斷最佳化的即時診斷系統的共存。應用領域包括提供攜帶者、診斷和預測服務的基因檢測；細菌、寄生蟲和病毒病原體的感染疾病檢測；利用液態切片、微量殘存疾病評估和組織切片檢查進行腫瘤監測；以及侵入性和非侵入性形式的產前檢測。

最終用戶範圍廣泛，從引領檢測方法開發的學術研究機構，到專注於高通量檢測的診斷實驗室，再到為第一線患者提供醫療服務的醫院和診所。這些細分市場擁有不同的資本強度、法規要求和應用曲線。了解產品、技術、檢體類型、檢測格式、應用領域和最終用戶特徵之間的相互關係，有助於相關人員協調策略舉措和產品系列，以應對不斷變化的臨床需求和市場動態。

市場成熟度投資趨勢凸顯了亞太地區分子診斷採用和醫療保健基礎設施的區域差異

美洲、歐洲、中東和非洲以及亞太地區多樣化的經濟、監管和醫療基礎設施因素共同塑造市場動態。在美洲，完善的報銷環境和大型診斷公司的集中度推動著先進檢測方法的快速普及，而官民合作關係則加速了液態切片和伴隨診斷等領域的創新。北美在監管透明度方面仍處於領先地位，各機構正在製定適應性核准途徑，並鼓勵整合真實世界數據。

歐洲、中東和非洲的成熟度水準參差不齊。西歐擁有統一的法律規範，並為精準醫療計畫提供了充足的資金；而中東地區則正在對醫療基礎設施和分子檢測能力進行策略性投資。感染疾病監測計畫正在推動一些非洲市場的成長，但實驗室能力和供應鏈可靠性方面仍面臨挑戰。跨國合作和能力建構工作正在幫助填補空白，並擴大服務欠缺地區的檢測管道。

亞太地區的特點是國內診斷製造商的快速擴張以及政府主導的加強基因組醫學的努力。中國、印度和日本等國家正在擴大定序中心和就地檢驗網路，以支持大規模篩檢和公共衛生監測。這些市場的監管機構正日益與國際標準接軌，從而促進高影響力檢測方法的快速核准。總而言之，這種區域多樣性凸顯了量身定做的參與策略和以本地為重點的夥伴關係關係的重要性，以充分利用不同的成長軌跡和醫療保健重點。

主要分子診斷主要企業的概況、影響市場動態的競爭策略、創新夥伴關係和研發投資

主要企業正透過對次世代定序能力的定向投資、試劑供應的策略聯盟以及人工智慧解讀工具的整合來脫穎而出。一些公司建立了專業中心，以加速檢測開發並簡化臨床驗證流程，而其他公司則透過併購來擴大產品系列併進入新興市場。透過與製藥公司的合作，伴隨診斷在臨床試驗設計和治療決策中發揮越來越重要的作用。

專注於數位PCR和快速照護現場平台等利基應用的中階市場公司也在不斷創新。這些公司注重敏捷性，利用模組化儀器架構和雲端基礎的分析流程來縮短部署時間並實現遠端監控。此外，診斷開發商和學術研究機構之間的合作正在開發針對罕見疾病和新型癌症生物標記的尖端檢測方法，這些合作通常由共同開發契約支持，這些協議既共用技術專長，也共擔商業化風險。

因此，競爭格局正朝著生態系統模式發展，產品供應商、軟體供應商和服務實驗室構成一個互聯互通的網路。這種方法增強了客戶的端到端解決方案，提供了從樣本採集到數據報告的無縫工作流程。能夠提供全面的產品、良好的監管記錄和可擴展的生產能力的公司最有可能獲得與醫療保健系統的長期契約，並在這個充滿活力的市場中保持優勢。

為產業領導者提供可行的策略建議，以利用新興的分子診斷機會，同時降低風險並簡化市場進入流程

為了在不斷變化的分子診斷環境中取得成功，產業領導者應優先考慮策略性投資組合多元化，拓展液態切片和數位PCR等高成長技術領域。開發適用於集中式實驗室工作流程和照護現場應用的模組化平台，將增強市場覆蓋率和韌性。同時，與試劑供應商和學術夥伴關係合作可以降低供應鏈風險並加快檢測檢驗。

領導者還需要深化與付款者和監管機構的合作，建立基於價值的報銷框架，獎勵以診斷主導的治療途徑。透過縱向研究和病患登記系統投資於現實世界證據的生成，將增強經濟價值提案。在營運方面，透過近岸外包和雙重採購安排最佳化製造佈局，可以抵消潛在關稅的影響，並確保關鍵的供應連續性。

此外，將人工智慧和機器學習融入您的數據分析流程，可以為您提供切實可行的洞察和預測能力，從而脫穎而出。採用數位連線來支援遠距離診斷和遠端醫療服務，可以幫助您滿足醫療服務提供者和患者不斷變化的需求。最後，在組織內培育持續學習和跨職能協作的文化，可以促進創新，並使其能夠快速適應新的市場趨勢和監管變化。

全面的調查方法詳細說明了資料收集、主要和次要資訊檢驗過程和分析框架，為分子診斷洞察奠定了基礎。

調查方法採用嚴格的多階段方法，以確保獲得全面且準確的洞察。主要研究透過對關鍵相關人員（包括實驗室主任、臨床研究人員和監管專家）的深入訪談進行。這些質性研究也輔以對醫院和獨立檢測機構決策者的結構化調查，以收集關於技術採用、營運挑戰和成長重點的第一手觀點。

我們的二次研究系統性地回顧了同行評審的科學文獻、監管文件和行業報告，以便將我們的主要研究結果納入更廣泛的市場和政策趨勢中。公司新聞稿、專利申請和財務揭露提供了有關競爭策略和創新軌蹟的詳細資訊。我們使用交叉驗證技術對資料點進行三角測量，以識別和協調不一致之處，確保研究的穩健性和可靠性。

此分析框架融合了定性主題分析和定量趨勢建模。細分分析透過與專家的迭代回饋循環進行完善，使市場分類與實際臨床工作流程一致。所有研究結果均經過嚴格的同行評審和品質保證檢查，以檢驗資料輸入的完整性和解釋性結論的有效性。此調查方法的嚴謹性確保了報告中提出的戰略建議和可操作情報的可信度。

分子診斷市場趨勢創新整合關鍵見解和策略要點，總結永續成長和復甦的挑戰和途徑

摘要：在技術創新、法規不斷演變和臨床應用不斷拓展的推動下，分子診斷市場正處於轉型成長的風口浪尖。產品、技術、檢體類型、檢測方式、應用和最終用戶的策略性細分揭示了一個複雜的生態系統，表明有針對性的投資和合作夥伴關係關係對於持續成功至關重要。區域動態進一步凸顯了採用客製化方法來應對多樣化醫療基礎設施和政策環境的必要性。

競爭優勢取決於企業能否整合高階分析技術，維持供應鏈韌性，並透過堅實的臨床和經濟證據展現實際的價值。上市公司若優先考慮敏捷性，並在集中式實驗室能力與分散式即時診斷 (POC) 解決方案之間取得平衡，將更有能力滿足常規診斷需求和公共衛生需求。此外，積極與監管機構和付款方溝通將有助於簡化核准，並建立有利的報銷途徑。

最終，它需要創新、協作和策略遠見的整合。憑藉對市場趨勢的實際洞察，相關人員可以預測變化、降低風險並抓住新機會。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 透過整合人工智慧驅動的分析平台轉變高通量分子診斷工作流程
  • 分散式次世代定序面板的引入使遠距醫療環境中的精準醫療成為可能
  • 用於非侵入性癌症篩檢和監測的多重液態生物檢體檢測的出現
  • 伴隨診斷的監管核准不斷增加，促進了全球個人化腫瘤治療方案的出現
  • 擴大基於 CRISPR 的即時診斷檢測的使用將實現快速病原體檢測
  • 微流體實驗室晶片平台的進步減少了分子檢測的測試量和周轉時間
  • 擴大採用數位 PCR 技術來提高罕見突變檢測的靈敏度和定量準確性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章分子診斷市場（依產品提供）

  • 裝置
  • 試劑和套件
  • 軟體和服務

第9章分子診斷市場（按技術）

  • 螢光原位雜合反應
  • 質譜法
  • 微陣列分析
  • 次世代定序
    • EXOME定序
    • RNA定序
    • 標靶定序
    • 全基因組序列分析
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 多重PCR
    • 即時PCR

第 10 章分子診斷市場（依檢體類型）

  • 血
  • 腦脊髓液（CSF）
  • 鼻/咽拭子
  • 唾液
  • 航班
  • 組織切片檢查
  • 尿

第 11 章分子診斷市場（依測試類型）

  • 基於實驗室
    • 中央研究院
    • 醫院檢查室
    • 獨立實驗室
  • 照護現場

第12章分子診斷市場（按應用）

  • 基因檢測
    • 職業測試
    • 診斷測試
    • 預測測試
  • 感染疾病
    • 細菌
    • 寄生蟲
    • 病毒性的
  • 腫瘤學
    • 液態生物檢體
    • 微量殘存疾病
    • 組織切片檢查
  • 產前檢查
    • 侵入性
    • 非侵入性

第 13 章 分子診斷市場（依最終使用者）

  • 學術研究機構
  • 診斷實驗室
  • 醫院和診所

第14章分子診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章分子診斷市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國分子診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories Inc.
    • ADT Biotech Co., Ltd.
    • AstraZeneca plc
    • Becton, Dickinson, and Company
    • Bio-Rad Laboratories, Inc.
    • Biocartis Group NV
    • bioMerieux SA
    • Castle Biosciences, Inc.
    • Danaher Corporation
    • Diasorin Sp,A.
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche AG
    • Grifols SA
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • Myriad Genetics, Inc.
    • Oxford Nanopore Technologies
    • QIAGEN NV
    • Siemens Healthineers AG
    • Source BioScience
    • Sysmex Corporation by Oxford Gene Technology
    • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D46

The Molecular Diagnostics Market is projected to grow by USD 81.60 billion at a CAGR of 14.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 28.02 billion
Estimated Year [2025] USD 31.86 billion
Forecast Year [2032] USD 81.60 billion
CAGR (%) 14.29%

Exploring the Molecular Diagnostics Market's Foundations Technological Innovations Clinical Drivers and Emerging Opportunities in Healthcare Delivery

Molecular diagnostics has emerged as a cornerstone of modern healthcare delivery by offering unprecedented precision in detecting, characterizing, and monitoring disease at the genetic and molecular levels. This field encompasses a broad array of assays and analytical platforms designed to identify specific genetic mutations, pathogens, and biomarkers, thereby enabling personalized treatment strategies and improving patient outcomes. Progress in assay sensitivity, coupled with the declining cost of sequencing and advanced imaging, has fueled widespread adoption of molecular diagnostic tools across clinical laboratories, research institutions, and point-of-care settings.

Technological breakthroughs in next-generation sequencing, polymerase chain reaction enhancements, and mass spectrometry have catalyzed the expansion of testing capabilities, while regulatory frameworks have adapted to accelerate approvals for innovative diagnostics. Concurrent investments in laboratory infrastructure and digital integration are reinforcing the interoperability of data systems, facilitating seamless flow of patient information and rapid clinical decision-making. Moreover, the convergence of diagnostics and therapeutics, often referred to as theranostics, positions molecular assays at the heart of targeted treatment protocols.

Looking ahead, the interplay of evolving regulatory landscapes, reimbursement strategies, and shifting clinical needs will determine the trajectory of market growth. Stakeholders must navigate complex operational challenges, including scalability, quality control, and supply chain resilience, while capitalizing on opportunities presented by emerging applications in oncology, infectious diseases, and genetic screening. The collective momentum behind molecular diagnostics underscores its critical role in reshaping patient care paradigms and driving the next frontier of precision medicine.

Unveiling the Disruptive Shifts Redefining Molecular Diagnostics from Personalized Medicine Integration to Regulatory Evolution and Technological Convergence in Clinical Testing

The molecular diagnostics landscape is undergoing a seismic transformation driven by advancements in assay technologies, data analytics, and therapeutic integration. Personalized medicine has shifted from theoretical promise to tangible reality as genomic profiling and biomarker-guided therapies become integral to oncology and rare disease management. This evolution is further amplified by digital pathology and artificial intelligence platforms that streamline image interpretation and predictive modeling, enhancing diagnostic precision.

Regulatory authorities are responding to these shifts with adaptive pathways designed to expedite market entry for high-impact assays, though this progress is accompanied by heightened scrutiny on clinical validation and post-market surveillance. At the same time, cost-containment pressures and demands for real-world evidence are compelling manufacturers to demonstrate value through outcome-based studies. The COVID-19 pandemic served as a catalyst, proving the agility of molecular diagnostic developers in scaling production of high-throughput tests and fostering public-private collaborations to address emergent health crises.

As a result, stakeholders are witnessing a convergence of decentralization trends and centralized laboratory capabilities. Point-of-care platforms have matured, offering rapid turnaround times and ease of use, while centralized labs continue to push the boundaries of multiplexed assays and ultra-high-throughput sequencing. This duality enables a more robust diagnostic ecosystem capable of responding to both routine screening needs and large-scale surveillance demands. Consequently, market players are reevaluating their portfolios and forging strategic alliances to align with these disruptive currents, ensuring resilience and relevance in a rapidly evolving environment.

Assessing the Comprehensive Effects of New United States Tariff Policies on Molecular Diagnostics Supply Chains Costs and Strategic Manufacturing Realignments by 2025

Anticipated changes to United States tariff policies by 2025 are poised to exert a profound influence on the molecular diagnostics industry's cost structures and supply chain strategies. With proposals to levy higher duties on imported reagents, instrumentation and ancillary components, manufacturers and laboratories brace for increased input costs that could be passed downstream to healthcare providers and patients. This scenario underscores the need for strategic sourcing and supply base diversification to mitigate exposure to tariff-induced price pressures.

In response, some instrument producers are examining options to localize assembly operations or to establish captive reagent manufacturing facilities within domestic borders. Such initiatives may alleviate tariff burdens but could entail significant capital investment and extended timelines to achieve regulatory compliance. Simultaneously, diagnostic developers are engaging in proactive negotiations with distributors to secure long-term supply contracts, adopting dual sourcing agreements and exploring nearshoring opportunities for critical materials.

The cumulative effect of these measures will reshape competitive dynamics as companies with robust vertical integration and supply chain agility gain a cost advantage. Meanwhile, smaller firms may struggle to absorb elevated duties without compromising profitability or passing costs to end users. Policy uncertainty further complicates investment decisions, compelling stakeholders to model various tariff scenarios and to establish contingency frameworks. In this climate, collaboration across the value chain-from raw material suppliers to end-user laboratories-will be essential to preserve access to cutting-edge molecular diagnostic solutions and to maintain continuity of patient care.

Deep Dive into Offerings Technologies Specimen Types Test Formats Application Areas and End User Profiles Driving Strategic Segmentation in Molecular Diagnostics

A nuanced exploration of the market reveals that each offering segment contributes unique value propositions, with instruments providing the hardware backbone, reagents and kits delivering the biochemical specificity, and software and services enabling data management and interpretive analytics. The technology landscape spans fluorescence in situ hybridization for chromosomal and gene mapping, mass spectrometry for proteomic analysis, microarray assays for parallel target screening, next-generation sequencing in its exome, RNA, targeted and whole-genome modalities, and polymerase chain reaction platforms encompassing digital, multiplex and real-time variants.

Specimen type diversity reflects the versatility of molecular assays, from blood and cerebrospinal fluid to nasal and throat swabs, saliva, stool, tissue biopsies and urine, each presenting distinct preprocessing and analytical requirements. Test type categorization underscores the coexistence of laboratory-based models-with central, hospital and independent lab infrastructures-and point-of-care systems optimized for rapid, decentralized diagnostics. Application areas span genetic testing through carrier, diagnostic and predictive services; infectious disease detection of bacterial, parasitic and viral pathogens; oncology monitoring via liquid biopsy, minimal residual disease assessment and tissue biopsy; and prenatal testing in invasive and noninvasive formats.

End users range from academic and research institutes pioneering assay development, to diagnostic laboratories specializing in high-throughput testing, and hospitals and clinics delivering frontline patient services. These segments exhibit varying capital intensity, regulatory demands and adoption curves. By understanding the interplay among offerings, technologies, specimen types, test formats, application areas and end-user profiles, stakeholders can tailor strategic initiatives and product portfolios to address evolving clinical needs and market dynamics.

Illuminating Regional Variations in Molecular Diagnostics Adoption Market Maturation Investment Trends and Healthcare Infrastructure Across Americas EMEA and Asia Pacific

Regional market dynamics are shaped by diverse economic, regulatory and healthcare infrastructure factors across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, a well-established reimbursement environment and concentration of leading diagnostic companies foster rapid adoption of advanced assays, while public-private partnerships accelerate innovation in areas such as liquid biopsy and companion diagnostics. North America remains a bellwether for regulatory clarity, with agencies pioneering adaptive approval pathways and encouraging real-world data integration.

Europe, the Middle East and Africa collectively present a mosaic of maturity levels. Western Europe benefits from harmonized regulatory frameworks and robust funding for precision medicine initiatives, whereas the Middle East is witnessing strategic investments in healthcare infrastructure and molecular testing capabilities. In select African markets, growth is driven by infectious disease surveillance programs, yet challenges persist around laboratory capacity and supply chain reliability. Cross-border collaborations and capacity-building efforts are helping to bridge gaps and to expand testing accessibility in underserved regions.

The Asia-Pacific region is characterized by rapid expansion of domestic diagnostics players and government-led initiatives to bolster genomic medicine. Countries such as China, India and Japan are scaling up sequencing centers and point-of-care testing networks to support large-scale screening and public health monitoring. Regulatory authorities in these markets are increasingly aligning with international standards, facilitating expedited approvals for high-impact assays. Collectively, this regional diversity underscores the importance of tailored entry strategies and localized partnerships to capitalize on varying growth trajectories and healthcare priorities.

Profiling Leading Molecular Diagnostics Companies Highlighting Competitive Strategies Innovations Partnerships and R&D Investments Shaping Market Leadership Dynamics

Leading companies in molecular diagnostics are distinguishing themselves through targeted investments in next-generation sequencing capabilities, strategic alliances for reagent supply and the integration of AI-driven interpretive tools. Some have established dedicated centers of excellence to accelerate assay development and to streamline clinical validation, while others pursue mergers and acquisitions to broaden their product portfolios and to gain access to emerging markets. Collaborative ventures with pharmaceutical firms are amplifying the role of companion diagnostics in clinical trial design and therapeutic decision-making.

Innovation is also thriving among mid-sized organizations that specialize in niche applications such as digital PCR or rapid point-of-care platforms. These players focus on agility, leveraging modular instrument architectures and cloud-based analytic pipelines to reduce deployment time and to enable remote monitoring. Furthermore, partnerships between diagnostic developers and academic research institutes are producing cutting-edge assays for rare diseases and novel oncology biomarkers, often underpinned by co-development agreements that share both technical expertise and commercialization risk.

As a result, the competitive landscape is evolving toward an ecosystem model in which product vendors, software providers and service laboratories form interconnected networks. This approach enhances end-to-end solutions for customers, offering seamless workflows from sample collection to data reporting. Companies that can demonstrate comprehensive offerings, strong regulatory track records and scalable manufacturing capabilities are best positioned to secure long-term contracts with healthcare systems and to maintain a leading edge in this dynamic market.

Actionable Strategic Recommendations for Industry Leaders to Capitalize on Emerging Molecular Diagnostics Opportunities While Mitigating Risks and Streamlining Market Entry

To thrive in the shifting molecular diagnostics environment, industry leaders should prioritize strategic portfolio diversification by expanding into high-growth technology areas such as liquid biopsy and digital PCR. Developing modular platforms that accommodate both centralized laboratory workflows and point-of-care applications will enhance market reach and resilience. Concurrently, forging partnerships with reagent suppliers and academic institutions can mitigate supply chain risks and accelerate assay validation.

Leaders must also deepen engagement with payers and regulatory bodies to establish value-based reimbursement frameworks that reward diagnostic-driven treatment pathways. Investing in real-world evidence generation through longitudinal studies and patient registries will strengthen economic value propositions. On the operational front, optimizing manufacturing footprints via nearshoring or dual sourcing arrangements can offset potential tariff impacts and ensure continuity of critical supplies.

Moreover, integrating artificial intelligence and machine learning into data analysis pipelines will differentiate offerings by delivering actionable insights and predictive capabilities. Embracing digital connectivity to support remote diagnostics and telehealth services will address evolving provider and patient needs. Finally, fostering a culture of continuous learning and cross-functional collaboration within organizations will expedite innovation and enable rapid adaptation to emerging market trends and regulatory changes.

Comprehensive Research Methodology Detailing Data Collection Primary and Secondary Sources Validation Processes and Analytical Frameworks Underpinning Molecular Diagnostics Insights

This research initiative employed a rigorous multi-phase methodology to ensure comprehensive and accurate insights. Primary data was gathered through in-depth interviews with key stakeholders, including laboratory directors, clinical researchers and regulatory experts. These qualitative engagements were complemented by structured surveys targeting decision-makers across hospital and independent laboratory settings, capturing firsthand perspectives on technology adoption, operational challenges and growth priorities.

Secondary research entailed systematic review of peer-reviewed scientific literature, regulatory filings and industry reports to contextualize primary findings within broader market and policy trends. Company press releases, patent filings and financial disclosures provided additional granularity on competitive strategies and innovation trajectories. Data points were triangulated through cross-validation techniques to identify and reconcile discrepancies, ensuring robustness and credibility.

Analytical frameworks incorporated both qualitative thematic analysis and quantitative trend modeling. Segmentation analyses were refined through iterative feedback loops with domain experts, aligning market categorizations with real-world clinical workflows. All findings underwent rigorous peer review and quality assurance checks, verifying the integrity of data inputs and the validity of interpretive conclusions. This methodological rigor underpins the reliability of strategic recommendations and the actionable intelligence presented throughout the report.

Synthesizing Key Insights and Strategic Imperatives to Conclude Molecular Diagnostics Market Trends Innovations Challenges and Pathways for Sustainable Growth and Resilience

In summary, the molecular diagnostics market stands at the cusp of transformative growth, propelled by technological innovations, regulatory evolutions and expanding clinical applications. Strategic segmentation across offerings, technologies, specimen types test formats applications and end users reveals a complex ecosystem where targeted investments and collaborative partnerships are essential to sustainable success. Regional dynamics further underscore the necessity of customized approaches to navigate diverse healthcare infrastructures and policy landscapes.

Competitive positioning will hinge on an organization's ability to integrate advanced analytics, maintain supply chain resilience and demonstrate tangible value through robust clinical and economic evidence. Companies that prioritize agility-balancing centralized laboratory capabilities with decentralized point-of-care solutions-will be well-equipped to address both routine diagnostic demands and emergent public health challenges. Moreover, proactive engagement with regulators and payers will facilitate streamlined approvals and favorable reimbursement pathways.

Ultimately, the path forward requires a harmonious blend of innovation, collaboration and strategic foresight. By leveraging actionable insights into market trends, stakeholders can anticipate shifts, mitigate risks and capitalize on emerging opportunities, thereby driving the next wave of precision medicine advancements and delivering improved patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven analysis platforms to transform high-throughput molecular diagnostics workflows
  • 5.2. Adoption of decentralized next-generation sequencing panels empowering precision medicine in remote healthcare settings
  • 5.3. Emergence of multiplexed liquid biopsy assays enabling noninvasive cancer screening and monitoring capabilities
  • 5.4. Increasing regulatory approvals for companion diagnostics fueling personalized oncology treatment selection globally
  • 5.5. Expanding use of CRISPR-based point-of-care diagnostic assays facilitating rapid pathogen detection
  • 5.6. Advancements in microfluidic lab-on-a-chip platforms to reduce assay volumes and turnaround times for molecular testing
  • 5.7. Rising implementation of digital PCR technologies to enhance sensitivity and quantification accuracy in rare mutation detection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Diagnostics Market, by Offering

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Molecular Diagnostics Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Mass Spectrometry
  • 9.3. Microarray Analysis
  • 9.4. Next-Generation Sequencing
    • 9.4.1. Exome Sequencing
    • 9.4.2. RNA Sequencing
    • 9.4.3. Targeted Sequencing
    • 9.4.4. Whole Genome Sequencing
  • 9.5. Polymerase Chain Reaction
    • 9.5.1. Digital PCR
    • 9.5.2. Multiplex PCR
    • 9.5.3. Real-Time PCR

10. Molecular Diagnostics Market, by Specimen Type

  • 10.1. Blood
  • 10.2. Cerebrospinal Fluid (CSF)
  • 10.3. Nasal/Throat Swabs
  • 10.4. Saliva
  • 10.5. Stool
  • 10.6. Tissue Biopsies
  • 10.7. Urine

11. Molecular Diagnostics Market, by Test Type

  • 11.1. Laboratory Based
    • 11.1.1. Central Lab
    • 11.1.2. Hospital Lab
    • 11.1.3. Independent Lab
  • 11.2. Point Of Care

12. Molecular Diagnostics Market, by Application

  • 12.1. Genetic Testing
    • 12.1.1. Carrier Testing
    • 12.1.2. Diagnostic Testing
    • 12.1.3. Predictive Testing
  • 12.2. Infectious Disease
    • 12.2.1. Bacterial
    • 12.2.2. Parasitic
    • 12.2.3. Viral
  • 12.3. Oncology
    • 12.3.1. Liquid Biopsy
    • 12.3.2. Minimal Residual Disease
    • 12.3.3. Tissue Biopsy
  • 12.4. Prenatal Testing
    • 12.4.1. Invasive
    • 12.4.2. Non-Invasive

13. Molecular Diagnostics Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals & Clinics

14. Molecular Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Molecular Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Molecular Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories Inc.
    • 17.3.2. ADT Biotech Co., Ltd.
    • 17.3.3. AstraZeneca plc
    • 17.3.4. Becton, Dickinson, and Company
    • 17.3.5. Bio-Rad Laboratories, Inc.
    • 17.3.6. Biocartis Group NV
    • 17.3.7. bioMerieux SA
    • 17.3.8. Castle Biosciences, Inc.
    • 17.3.9. Danaher Corporation
    • 17.3.10. Diasorin S.p,A.
    • 17.3.11. Exact Sciences Corporation
    • 17.3.12. F. Hoffmann-La Roche AG
    • 17.3.13. Grifols S.A.
    • 17.3.14. Guardant Health, Inc.
    • 17.3.15. Hologic, Inc.
    • 17.3.16. Illumina, Inc.
    • 17.3.17. Laboratory Corporation of America Holdings
    • 17.3.18. Myriad Genetics, Inc.
    • 17.3.19. Oxford Nanopore Technologies
    • 17.3.20. QIAGEN N.V.
    • 17.3.21. Siemens Healthineers AG
    • 17.3.22. Source BioScience
    • 17.3.23. Sysmex Corporation by Oxford Gene Technology
    • 17.3.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2